{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:15:55Z","timestamp":1761920155150,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.msard.2016.05.020","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T19:07:06Z","timestamp":1464894426000},"page":"141-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Erythroblastaemia in natalizumab-treated patients with multiple sclerosis"],"prefix":"10.1016","volume":"8","author":[{"given":"Sara","family":"La Gioia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Seghezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Barcella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Dominoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Mecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Frigeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Zaffira","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"Vedovello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Vidali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosa","family":"Rottoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Buoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2016.05.020_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1532\/LH96.05019","article-title":"The international consensus group for hematology review: suggested criteria for action following automated CBC and WBC differential analysis","volume":"11","author":"Barnes","year":"2005","journal-title":"Lab. Hematol."},{"issue":"7","key":"10.1016\/j.msard.2016.05.020_bib2","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2007-09-112052","article-title":"Increased numbers of circulating hematopoietic stem\/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab","volume":"111","author":"Bonig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.msard.2016.05.020_bib3","unstructured":"McEnroe, R.J., Durham, A.P., Goldford, M.D., et al., 2014. Evaluation of Precision of Quantitative Measurement Procedures \u2013 Approved Guideline, third edition. CLSI Guideline EP05-A3E, Wayne, PA."},{"issue":"2","key":"10.1016\/j.msard.2016.05.020_bib4","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1212\/NXI.0000000000000123","article-title":"Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study","volume":"18","author":"Bridel","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2016.05.020_bib5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/jclinpath-2012-200930","article-title":"Performance evaluation of the Sysmex haematology XN modular system","volume":"65","author":"Briggs","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"11","key":"10.1016\/j.msard.2016.05.020_bib6","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/jclinpath-2012-200930","article-title":"Performance evaluation of the Sysmex haematology XN modular system","volume":"65","author":"Briggs","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.msard.2016.05.020_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/ijlh.12201","volume":"36","author":"Briggs","year":"2014","journal-title":"Int. J. Lab. Hematol."},{"issue":"7","key":"10.1016\/j.msard.2016.05.020_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1515\/cclm-2014-0945","article-title":"Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000","volume":"53","author":"Bruegel","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"issue":"5","key":"10.1016\/j.msard.2016.05.020_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200702080","article-title":"Alpha4beta1 integrin and erythropoietin mediate temporally distinct steps in erythropoiesis: integrins in red cell development","volume":"177","author":"Eshghi","year":"2007","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.msard.2016.05.020_bib10","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.V87.6.2513.bloodjournal8762513","article-title":"A critical role of VLA-4 in erythropoiesis in vivo","volume":"87","author":"Hamamura","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.msard.2016.05.020_bib11","unstructured":"Koepke, J.A.,\u00a0van Assendelft, O.W., Brindza, L.J., et al., 2010. Reference Leukocyte (WBC) Differential Count (Proportional) and Evaluation of instrumental Methods - Approved Standard, second ed. CLSI document H20A2, Wayne, PA."},{"issue":"14","key":"10.1016\/j.msard.2016.05.020_bib12","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0000000000001454","article-title":"Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis","volume":"84","author":"Mattoscio","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2016.05.020_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2016.05.020_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/ijlh.12327","article-title":"ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features","volume":"37","author":"Palmer","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"issue":"9","key":"10.1016\/j.msard.2016.05.020_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.msard.2016.05.020_bib16","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2016.05.020_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/1352458514521307","article-title":"The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis","volume":"20","author":"Robier","year":"2014","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2016.05.020_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering","volume":"5","author":"Sutherland","year":"1996","journal-title":"J. Hematother."},{"issue":"3","key":"10.1016\/j.msard.2016.05.020_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ijlh.12291","article-title":"Performance evaluation of the automated nucleated red blood cell enumeration on Sysmex XN analyser","volume":"37","author":"Tantanate","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"issue":"1","key":"10.1016\/j.msard.2016.05.020_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1352458510383075","article-title":"Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment","volume":"17","author":"Wipfler","year":"2011","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2016.05.020_bib21","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","article-title":"The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans","volume":"111","author":"Zohren","year":"2008","journal-title":"Blood"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816300840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034816300840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:39:30Z","timestamp":1761899970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034816300840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":21,"alternative-id":["S2211034816300840"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2016.05.020","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythroblastaemia in natalizumab-treated patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2016.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}